gsk201510206k2.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
 
The Administrators of the GlaxoSmithKline US Deferred Performance Share Plan (the 'Plan') notified GlaxoSmithKline plc (the 'Company') on 19 October 2015 that the under-mentioned Director and Person Discharging Managerial Responsibilities ('PDMR') acquired American Depositary Shares ('ADSs') at a price of $38.74 per ADS following the re-investment of the dividend paid to shareholders on 1 October 2015.
 
 
 
Director/PDMR
 
ADSs
Dr M M Slaoui
310.421
Mr D E Troy
417.636
 
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
 
V A Whyte
Company Secretary
 
20 October 2015
 
 
                                                                                                                                                                            SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 20, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc